Xeris announced last month the beginning of its phase 2 trial of a room temperature stabilized glucagon. The trial will compare Xeris’ glucagon to Eli Lilly’s glucagon...

On April 3, an FDA Advisory Committee voted an overwhelming 13-1 in favor of approving MannKind’s ultra-rapid-acting inhaled insulin Afrezza for type 1 diabetes. The...

Downloading data, CGMs and insurance coverage, and how the Mediterranean diet is good for your heart.

Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) released its safety review of incretin-based therapies for diabetes. It...

MannKind’s inhalable ultra-rapid-acting insulin Afrezza has its day at the FDA – find out what it can do for patients and how to speak up!

On January 8, the FDA approved Farxiga (dapaglifozin) for the treatment of type 2 diabetes. The drug is called Forxiga in Europe, where it has been approved since...

On April 17, Abbott announced a recall of the FreeStyle InsuLinx blood glucose meters due to software issues for readings of 1,024 mg/dl and above. The problem is...

An open letter to the FDA’s Dr. Margaret Hamburg from diaTribe .

This November will be the third annual World Diabetes Day Postcard Exchange, where people from around the world will send and receive handmade postcards to celebrate...

On January 13, J&J LifeScan announced the launch of the OneTouch VerioSync blood glucose meter in the US. The meter sends blood glucose readings wirelessly (via...

We’re super proud to see our home city of San Francisco taking a stand against soda and sugary beverages and recognizing their role in the rising rates of obesity and...

The International Diabetes Federation (IDF) is holding the Take a Step for Diabetes campaign to increase awareness for diabetes. This “step” can be a variety of actions...

The three top trends we saw in diabetes in 2013.

Eli Lilly announced in October the submission of dulaglutide, its once-weekly GLP-1 receptor agonist for type 2 diabetes, in the US and Europe. This means a regulatory...

On April 15, the FDA approved GlaxoSmithKline’s once-weekly GLP-1 agonist Tanzeum (albiglutide) for type 2 diabetes, which makes it the second once-weekly GLP-1 agonist...

(S)he said what!?

On July 30, Ambio Health announced FDA clearance of its Remote Health Monitoring System , which can wirelessly send readings from the AgaMatrix Presto blood glucose...

(S)he said what!?

On November 22, J&J/Janssen Cilags’ SGLT-2 inhibitor Invokana (canagliflozin) was approved in Europe. This makes Invokana the second SGLT-2 inhibitor approved in...

On January 21, Glooko and Joslin announced a partnership to develop a new web/mobile-based diabetes management platform. The system will combine a “Virtual Joslin”...